DUBLIN--(BUSINESS WIRE)--Apr 5, 2018--The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the details in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2012 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Key benefits

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 provides the reader with the following key benefits

  • In-depth understanding of clinical stage deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of clinical stage agreements with numerous real life case studies
  • Insight into the terms included in a clinical stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Trends in clinical stage dealmaking in the biopharma industry since 2012
  • Analysis of clinical stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life clinical stage deals
  • Access to over 2,000 clinical stage deals
  • The leading clinical stage deals by value since 2012
  • Most active clinical stage dealmakers since 2012
  • The leading clinical stage partnering resources

Available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

For more information about this report visit https://www.researchandmarkets.com/research/khwlg2/global_pharma_and?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180405006101/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biotechnology,Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 04/05/2018 02:43 PM/DISC: 04/05/2018 02:43 PM

http://www.businesswire.com/news/home/20180405006101/en